Can Mid-Cap Lantheus Continue its 2022 Outperformance?

Published on October 28, 2022

Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.